Slingshot members are tracking this event:

AbbVie (ABBV) Phase 3 ENDURANCE-3 Data Evaluating Glecaprevir/Pibrentasvir in Difficult-to-Treat Genotype 3 HCV Patients Without Cirrhosis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 21, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Endurance-3, Glecaprevir, Pibrentasvir, Difficult-to-treat, Genotype 3, International Liver Congress